drugset / Trial / NCT06297642

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

NCT06297642

Phase 1 Terminated 3 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

Timeline

Start
2024-05-24
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Penpulimab Monoclonal antibody
Subject TQB2928 Monoclonal antibody

Indications